Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142281 | 0.90 | KCNH2 (0.56) | KCNH2MAPK1KDM4EPOLBL3MBTL1 | |
| SCHEMBL3605800 | 0.88 | KCNH2 (0.72) | KCNH2TSHRMAPK1KDM4EPOLB | |
| SCHEMBL1619314 | 0.88 | KCNH2 (0.72) | KCNH2TSHRMAPK1KDM4EPOLB | |
| SCHEMBL4134400 | 0.82 | KCNH2 (0.67) | KCNH2MAPK1KDM4EPOLBL3MBTL1 | |
| SCHEMBL4128937 | 0.82 | KCNH2 (0.67) | KCNH2MAPK1KDM4EPOLBL3MBTL1 | |
| SCHEMBL4134172 | 0.82 | KCNH2 (0.66) | KCNH2MAPK1KDM4EPOLBL3MBTL1 | |
| SCHEMBL4134243 | 0.81 | KCNH2 (0.54) | KCNH2TSHRMAPK1KDM4EPOLB | |
| SCHEMBL4139906 | 0.81 | KCNH2 (0.56) | KCNH2TSHRMAPK1KDM4EPOLB | |
| SCHEMBL1619251 | 0.80 | KCNH2 (0.48) | KCNH2TSHRMAPK1KDM4EPOLB | |
| SCHEMBL1619266 | 0.79 | KCNH2 (0.58) | KCNH2MAPK1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885TSHR 1242/4885MAPK1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.